Illumina
eröffnet am 22.11.18 09:39:01 von
neuester Beitrag 04.05.24 14:39:11 von
neuester Beitrag 04.05.24 14:39:11 von
Beiträge: 65
ID: 1.293.106
ID: 1.293.106
Aufrufe heute: 0
Gesamt: 9.176
Gesamt: 9.176
Aktive User: 0
ISIN: US4523271090 · WKN: 927079 · Symbol: ILMN
111,35
USD
+0,66 %
+0,73 USD
Letzter Kurs 02:00:00 Nasdaq
Meistbewertete Beiträge
| Datum | Beiträge | Bewertungen |
|---|---|---|
| 04.05.24 | ||
| 04.05.24 |
| Datum | Beiträge | Bewertungen |
|---|---|---|
| 04.05.24 | ||
| 04.05.24 |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2000 | +93,94 | |
| 1,0300 | +37,44 | |
| 1,3300 | +30,51 | |
| 1,9950 | +27,48 | |
| 21,010 | +26,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | -17,81 | |
| 7,5000 | -20,97 | |
| 2,4650 | -27,50 | |
| 4,6600 | -41,60 | |
| 2,0400 | -51,31 |
Beitrag zu dieser Diskussion schreiben
Feedback
Reuters
Illumina reaffirms annual revenue forecast over continued sluggish demand
May 2 (Reuters) -Illumina ILMN.O reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.
The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.
The company said it is on track to divest cancer diagnostic test maker Grail GRAL.O and expects to finalize terms by the second quarter.
U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.
On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts' average estimate of 4 cents per share.
Shares of the company fell to 2.4% at $121 in aftermarket trading.
https://www.xm.com/research/markets/allNews/reuters/illumina…
Illumina reaffirms annual revenue forecast over continued sluggish demand
May 2 (Reuters) -Illumina ILMN.O reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.
The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.
The company said it is on track to divest cancer diagnostic test maker Grail GRAL.O and expects to finalize terms by the second quarter.
U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.
On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts' average estimate of 4 cents per share.
Shares of the company fell to 2.4% at $121 in aftermarket trading.
https://www.xm.com/research/markets/allNews/reuters/illumina…
Illumina: EPS übertrifft Schätzungen um 0,05 $ - Umsatz besser als erwartet
https://de.investing.com/news/stock-market-news/illumina-eps…
https://de.investing.com/news/stock-market-news/illumina-eps…
Heute Abend nach Börsenschluss Quartalszahlen. Ich bin gespannt.
mMn ist Illumina der „Schaufelhersteller“ für genau diesen Bereich:
https://www.focus.de/gesundheit/ratgeber/krebs/krebsmedizine…
https://www.focus.de/gesundheit/ratgeber/krebs/krebsmedizine…
„Give Someone a Fish, You Feed Them - Unlock the Fish Genome, You Feed the World“
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Illumina
WorldFish and the Earlham Institute are using genomics to improve tilapia for the sake of global food sustainability
https://www.finanznachrichten.de/nachrichten-2024-03/6161778…
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Illumina
WorldFish and the Earlham Institute are using genomics to improve tilapia for the sake of global food sustainability
https://www.finanznachrichten.de/nachrichten-2024-03/6161778…
Trading Spotlight
https://www.fool.com/investing/2024/02/26/why-illumina-stock…
The biotech reported a pack of share purchases by a key insider.
CEO Jacob Thaysen more than doubled his holdings.
The biotech reported a pack of share purchases by a key insider.
CEO Jacob Thaysen more than doubled his holdings.
Durchsuchen
Illumina
